Expertise in
5
conditions

Dr. Morand Piert

Nuclear Medicine
University Of Michigan Medical Center
1500 E Medical Center Dr, 
Ann Arbor, MI 
Expertise in
5
conditions
University Of Michigan Medical Center
1500 E Medical Center Dr, 
Ann Arbor, MI 

Overview

Morand Piert is a Nuclear Medicine provider practicing medicine in Ann Arbor, Michigan.

Dr. Piert is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Melorheostosis, Osteopenia, Melorheostosis with Osteopoikilosis, Prostatectomy, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 44 peer reviewed articles and participating in 4 clinical trials.

Specialties

Nuclear Medicine

Licenses

Nuclear Medicine in MI

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Priority Health
  • HMO
  • POS

Locations

University of Michigan Medical Center
1500 E Medical Center Dr, Ann Arbor, MI 48109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug, Other
Study Drug: 177Lu-PSMA-617
Study Phase: Phase 3
A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer
A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Diagnostic test, Drug
Study Phase: Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)
A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)
Enrollment Status: Completed
Publish Date: April 10, 2019
Intervention Type: Drug, Diagnostic test
Study Phase: Phase 3
Biodistribution and Mechanism of Action of the 11C-labeled PET Tracer Sarcosine in Patients With Prostate Cancer as Well as Radiation Dosimetry, Plasma Pharmacokinetics and Biodistribution in Healthy Volunteers
Biodistribution and Mechanism of Action of the 11C-labeled PET Tracer Sarcosine in Patients With Prostate Cancer as Well as Radiation Dosimetry, Plasma Pharmacokinetics and Biodistribution in Healthy Volunteers
Enrollment Status: Completed
Publish Date: November 09, 2017
Intervention Type: Drug
View 3 Less Clinical Trials

44 Total Publications

Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung Cancer.
Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 04, 2024
Similar Doctors
Expertise in
14
conditions
Dr. Nicolaas I. Bohnen
Nuclear Medicine | Neurology
Expertise in
14
conditions
Dr. Nicolaas I. Bohnen
Nuclear Medicine | Neurology

U Of M Radiology Nuclear Medicine

1500 E Medical Center Dr, Spc 5000, 
Ann Arbor, MI 
 (0.2 miles away)
734-936-4000
Languages Spoken:
English
See accepted insurances

Nicolaas Bohnen is a Neurologist and a Nuclear Medicine provider practicing medicine in Ann Arbor, Michigan. Dr. Bohnen is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Parkinson's Disease, Movement Disorders, Osteopenia, Melorheostosis, and Deep Brain Stimulation.

Expertise in
32
conditions
Dr. Kirk A. Frey
Nuclear Medicine | Neurology
Expertise in
32
conditions
Dr. Kirk A. Frey
Nuclear Medicine | Neurology

University Hospital

1500 E Medical Center Dr, Floor B1 Reception C, 
Ann Arbor, MI 
 (0.2 miles away)
734-232-6072
Languages Spoken:
English
See accepted insurances

Kirk Frey is a Neurologist and a Nuclear Medicine provider practicing medicine in Ann Arbor, Michigan. Dr. Frey is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Parkinson's Disease, Movement Disorders, Neuroendocrine Tumor, Osteopenia, and Hormone Replacement Therapy (HRT).

Expertise in
6
conditions
Dr. Milton D. Gross
Nuclear Medicine | Endocrinology | Internal Medicine
Expertise in
6
conditions
Dr. Milton D. Gross
Nuclear Medicine | Endocrinology | Internal Medicine

U Of M Radiology Nuclear Medicine

1500 E Medical Center Dr, Spc 5000, 
Ann Arbor, MI 
 (0.2 miles away)
734-936-4000
Languages Spoken:
English
See accepted insurances

Milton Gross is an Internal Medicine specialist and an Endocrinologist practicing medicine in Ann Arbor, Michigan. Dr. Gross is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Melorheostosis, Osteopenia, Melorheostosis with Osteopoikilosis, and Postmenopausal Osteoporosis. Dr. Gross is board certified in Nuclear Medicine and Internal Medicine.

Frequently Asked Questions about Dr. Morand Piert

How do I make an appointment with Dr. Morand Piert?

You can book an appointment with Dr. Morand Piert by calling their office at 734-936-5090. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Morand Piert a top-rated expert for Melorheostosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Morand Piert is classified as an Distinguished expert for Melorheostosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Morand Piert specialize in?

While Dr. Morand Piert is a Nuclear Medicine, they have specific expertise in Melorheostosis, Osteopenia, and Melorheostosis with Osteopoikilosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Nuclear Medicine.

Does Dr. Morand Piert participate in research or clinical trials?

Yes. Dr. Morand Piert has published 44 articles and abstracts on conditions like Melorheostosis. You can view a list of Dr. Morand Piert's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Morand Piert accept my insurance?

Dr. Morand Piert accepts most major insurance plans, including Blue Cross Blue Shield and Humana. We recommend calling the office directly at 734-936-5090 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Piert's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile